These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28478151)

  • 1. Ruxolitinib for the Treatment of Portal Hypertension in a Patient With Primary Myelofibrosis.
    Tan HK; Leow WQ; Chang PE
    Gastroenterology; 2019 Nov; 157(5):e26-e27. PubMed ID: 28478151
    [No Abstract]   [Full Text] [Related]  

  • 2. Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.
    Del Rosario M; Tsai H; Dasanu CA
    J Oncol Pharm Pract; 2018 Apr; 24(3):226-228. PubMed ID: 28436280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does ruxolitinib prolong the survival of patients with myelofibrosis?
    Cervantes F; Pereira A
    Blood; 2017 Feb; 129(7):832-837. PubMed ID: 28031182
    [No Abstract]   [Full Text] [Related]  

  • 4. Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis.
    Koschmieder S; Jost E; Cornelissen C; Müller T; Schulze-Hagen M; Bickenbach J; Marx G; Kleines M; Marx N; Brümmendorf TH; Dreher M
    Eur J Haematol; 2020 Nov; 105(5):655-658. PubMed ID: 32593209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.
    Maffioli M; Giorgino T; Mora B; Iurlo A; Elli E; Finazzi MC; Caramella M; Rumi E; Carraro MC; Polverelli N; D'Adda M; Malato S; Rossi M; Molteni A; Vismara A; Sissa C; Spina F; Anghilieri M; Cattaneo D; Renso R; Bellini M; Pioltelli ML; Cavalloni C; Barraco D; Accetta R; Bertù L; Della Porta MG; Passamonti F
    Blood Adv; 2019 Nov; 3(21):3196-3200. PubMed ID: 31698448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelofibrosis patients can develop extramedullary complications including renal amyloidosis and sclerosing hematopoietic tumor while otherwise meeting traditional measures of ruxolitinib response.
    Babushok DV; Nelson EJ; Morrissette JJD; Joshi S; Palmer MB; Frank D; Cambor CL; Hexner EO
    Leuk Lymphoma; 2019 Mar; 60(3):852-855. PubMed ID: 30227762
    [No Abstract]   [Full Text] [Related]  

  • 7. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
    Pugliese N; Giordano C; Nappi D; Luciano L; Cerchione C; Annunziata M; Casale B; Crisà E; Villa MR; Pezzullo L; Iovine M; Picardi M; Grimaldi F; Pane F; Martinelli V
    Cancer Med; 2019 Jun; 8(6):2802-2809. PubMed ID: 30997748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.
    Marchetti M; Barosi G; Cervantes F; Birgegård G; Griesshammer M; Harrison C; Hehlmann R; Kiladjian JJ; Kröger N; McMullin MF; Passamonti F; Vannucchi A; Barbui T
    Leukemia; 2017 Apr; 31(4):882-888. PubMed ID: 27740634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombocytopenia in patients with myelofibrosis: management options in the era of JAK inhibitor therapy.
    Benevolo G; Elli EM; Guglielmelli P; Ricco A; Maffioli M
    Leuk Lymphoma; 2020 Jul; 61(7):1535-1547. PubMed ID: 32093511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tuberculosis reactivation related with ruxolitinib in a patient with primary myelofibrosis.
    Pepeler MS; Özkurt ZN; Güzel ÖT; Akyürek N
    J Infect Dev Ctries; 2018 Oct; 12(10):926-928. PubMed ID: 32004164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Verruconis gallopava in a patient with myelofibrosis on ruxolitinib.
    Hsu A; Ulici V
    Blood; 2020 Apr; 135(14):1189. PubMed ID: 32243521
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of Patients with Early Myelofibrosis: A Discussion of Best Practices.
    Bose P
    Curr Hematol Malig Rep; 2024 Jun; 19(3):111-119. PubMed ID: 38441783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis.
    Maccaferri M; Leonardi G; Marasca R; Colaci E; Paolini A; Soci F; Forghieri F; Potenza L; Narni F; Luppi M
    Leuk Lymphoma; 2014 Sep; 55(9):2207-8. PubMed ID: 24354678
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib.
    Iurlo A; Cattaneo D; Boiocchi L; Orofino N; Fermo E; Cortelezzi A; Gianelli U
    Ann Hematol; 2015 Oct; 94(10):1749-51. PubMed ID: 26082334
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis.
    Mascarenhas J; Baer MR; Kessler C; Hexner E; Tremblay D; Price L; Sandy L; Weinberg R; Pahl H; Silverman LR; Goldberg JD; Kosiorek H; Dueck AC; Hoffman R
    Leuk Lymphoma; 2019 May; 60(5):1343-1345. PubMed ID: 30668266
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.
    Miyawaki H; Kioka H; Sato K; Kurashige M; Ozawa T; Shibayama H; Hikoso S; Morii E; Yamauchi-Takihara K; Sakata Y
    Intern Med; 2020 Jan; 59(2):229-233. PubMed ID: 31534088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?
    Molica M; Serrao A; Saracino R; Zacheo I; Stingone C; Alimena G; Breccia M
    Ann Hematol; 2014 Nov; 93(11):1951-2. PubMed ID: 24801017
    [No Abstract]   [Full Text] [Related]  

  • 18. Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients.
    Bjørn ME; Holmström MO; Hasselbalch HC
    Leuk Lymphoma; 2016; 57(1):125-8. PubMed ID: 25936872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA approves fourth JAK inhibitor for myelofibrosis.
    Mullard A
    Nat Rev Drug Discov; 2023 Nov; 22(11):862. PubMed ID: 37803081
    [No Abstract]   [Full Text] [Related]  

  • 20. [Syndrome of extrahepatic portal hypertension and chronic abdominal ischemia in patient with subleukemic myelosis and congenital immunodeficiency].
    Lukina EA; Sysoeva EP; Kitsenko EA; Varlamova EIu; Inozemtseva MV; Semenova EA; Nadinskaia MIu; Ivashkin VT
    Ter Arkh; 2009; 81(7):82-4. PubMed ID: 19708581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.